SME
IPO ·
BSE SME
Accretion Nutraveda Ltd
Listed
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms, including tablets, capsules, oral liquids, powders, oils, and external preparations like ba
Issue details
Price band
₹122 – ₹129
Face value
₹10
Lot size
1,000 shares
Minimum investment
₹2,58,000
Issue size
₹24.77 Cr
Fresh issue
₹23.53 Cr
Offer for sale
—
Issue type
Book Built
Exchange
BSE SME
Key dates
Opens
28 Jan 2026
Closes
30 Jan 2026
UPI mandate cut-off
5:00 PM on 30 Jan 2026
Allotment
2 Feb 2026
Refunds
3 Feb 2026
Shares in demat
3 Feb 2026
Listing
4 Feb 2026
Subscription and listing
Subscription
1.62x
Listing price
₹191
Registrar
Kfin Technologies Ltd
Lead manager
Sobhagya Capital Options
Subscription by category
Total
1.62x
Total applications
805
Anchor investors
Amount raised
₹7.02 Cr
Bid date
27 Jan 2026
50% lock-in ends
3 Mar 2026
Rest lock-in ends
2 May 2026
Listing day
Issue price
₹129
Open
₹191.00
High
₹200.55
Low
₹190.50
Day close
₹191.20
Listing gain at open
+48.06%
Issue structure
Shares reserved per category and share of the total issue
QIB Shares Offered
9,08,000
47.29%
Anchor Investor Shares Offered
5,44,000
28.33%
QIB (Ex. Anchor) Shares Offered
3,64,000
18.96%
NII Shares Offered
2,76,000
14.37%
bNII > ₹10L
1,84,000
9.58%
sNII < ₹10L
92,000
4.79%
Retail Shares Offered
6,40,000
33.33%
Market Maker Shares Offered
96,000
5.00%
Total Shares Offered
19,20,000
100.00%
Finaccle’s quick read
Apply
FY25 income up 209%, PAT up 218%, ROE 68.54%, D/E 0.54, post-issue P/E 20.02x.
A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.
About the company
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms, including tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels. The company operates as a Contract Development and Manufacturing Organization (CDMO) , serving both domestic and international markets such as Sri Lanka, Singapore, and the USA. Its products combine classical Ayurvedic principles with modern nutraceutical science to address areas like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness.
Founded
Promoters
Promoter holding
Financial performance
Period
PAT
ROE
68.54%
ROCE
49.09%
Debt / equity
0.54
PAT margin
16.59%
P/E post issue
20.02
Market cap
₹93.40 Cr
Use of IPO money
Purchase of Machineries for Automation in existing Manufacturing unit
₹4.22 Cr
Purchase of Machineries for New Manufacturing Setup
₹8.03 Cr
Funding working capital requirements of the Company
₹5.50 Cr
General Corporate Purposes
₹3.69 Cr
Issue Expenses
₹3.33 Cr
Strengths
✓
Revenue up 209% in FY25 to ₹16.06 Cr
✓
PAT up 218% in FY25 to ₹2.61 Cr
✓
PAT margin of 16.59%
✓
ROE of 68.54% and ROCE of 49.09%
✓
Moderate leverage: debt to equity 0.54
Risks to watch
!
SME platform: large lot size and thinner trading liquidity
Planning to take your own company public?
Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.
Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.
Last updated:
Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.